Gorsky says no tax inversion for J&J; FDA seeks advice on risks of testosterone drugs; Lilly unhappy about India's price caps;

@FiercePharma: AbbVie finally gets Shire, and oh so much more. News | Follow @FiercePharma

@TracyStaton: $GSK just can't escape China questions. Ex-workers sue, news of 2001 corruption breaks. More | Follow @TracyStaton

@EricPFierce: Teva says it is cooperating with probe by Israel into source of blood infections taking Teva product. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Dengue, polio and a less-than-ideal Q2 for the $NVS vax unit. All in this week's issue of FierceVaccines. Issue | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) CEO Alex Gorsky says the company is not scouting for any deal that would allow it to do a tax inversion as many competitors have. Story

> The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17 to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy. Item

> More than 100 people killed on the Malaysian Airlines flight that is believed shot down over the Russian-Ukraine border were headed for the AIDS 2014 conference in Australia. Story

> The National Institute for Health and Care Excellence (NICE) is recommending treatments for anyone with a 10% risk of developing cardiovascular disease to be put on treatment that could include a statin, which compares with the current standard of 20% risk. Article

> Eli Lilly ($LLY) has expressed concerns about India's broadening of price controls on drugs. Story

Medical Device News

@FierceMedDev: Stryker delivers positive Q2 numbers but stays mum on inversion. Story | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. More | Follow @MichaelGFierce

@EmilyWFierce: AbbVie found its pot of gold at the end of the rainbow, scooping up Shire and saving an estimated $1.3B by 2020. Article | Follow @EmilyWFierce

> Investments in Minnesota life science companies take big Q2 jump. Story

> Baxter International gets Q2 infusion from acquisition of Swiss dialysis outfit. Article

> Venture capitalist spending bonanza lifts med tech investment in Q2. Report

Biotech News

@FierceBiotech: This week's hirings and retirings: Merck KGaA brings on U.S. Merck's Rossetti to head R&D. More | Follow @FierceBiotech

@DamianFierce: AbbVie's Gonzalez says inversion debate should shift toward tax reform, "making U.S. companies more competitive in the global economy." | Follow @DamianFierce

@EmilyMFierce: Extra dose of inactivated polio vaccine provides greater protection in children. Story | Follow @EmilyMFierce

> Biotech VCs bet $1.8B in a colossal Q2. Report

> Baxter International gets Q2 infusion from acquisition of Swiss dialysis outfit. Story

> Amgen's kidney dialysis drug clears its first Phase III hurdle. Article

And Finally... AstraZeneca ($AZN) says that its new R&D center in Cambridge, U.K., will include glass-walled labs to promote "visible science." Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.